Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL's rocketing shares.

CSL Ltd (ASX: CSL) shares have staged a remarkable recovery since plumbing a multi-year closing low of just $92.24 on 3 June.

How remarkable?

Well, in mid-day trade on Tuesday, shares in the S&P/ASX 200 Index (ASX: XJO) biotech giant were trading for $180.17 apiece. This sees the CSL share price up 95.3% in less than four months. That compares to a 0.4% loss posted by the ASX 200 over this same period.

And this doesn't include the unfranked $2.244 a share final CSL dividend. While that passive income payout won't be made until 2 October, CSL stock traded ex-dividend on 9 September.

If we add that back into Tuesday's share price, then the accumulated value of CSL shares has soared 97.8% since the 3 June lows.

CSL trades on an unfranked 2.3% trailing dividend yield.

But following this meteoric recovery, and noting that CSL stock remains down more than 43% since August 2024, is the Aussie biotech company still a good buy today?

Buy and sell written on red dice on top of stock market charts.

Image source: Getty Images

CSL shares: Buy, hold or sell?

Catapult Wealth's Dylan Evans recently ran his slide rule over the ASX biotech giant (courtesy of The Bull).

"The CSL share price has partially recovered after the company posted a brighter outlook at its 2026 full year results," he noted.

"A promising sign was profit growth guidance in full year 2027, driven by the core blood plasma business," he added.

Connecting the dots, Evans issued a hold recommendation on CSL shares for now.

He concluded:

This guidance should provide the market with confidence about CSL's brighter future after a difficult period. There's potential value in the stock, particularly if CSL achieves guidance and growth recovers.

What's been sending the ASX 200 biotech stock soaring?

CSL reported its full year FY 2026 results on 18 August.

Although revenue declined 1% from FY 2025, and CSL reported net loss after tax of US$2.6 billion, investors were more focused on the company's profit growth guidance that Evans mentioned above.

For the full year FY 2027, management forecast steady revenue and underlying NPAT growth of approximately 5%.

"FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth," CSL interim CEO Gordon Naylor said on the day.

Naylor added:

We have made solid progress on our transformation program and continue to simplify the business. We have also invested in our commercial capabilities and development programs to drive top line growth in the future.

CSL shares closed up 17.3% on the day of the results release.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »